MSD Animal Health offers products for multiple species and diseases. AQUAVAC® Strep Sa is an injectable vaccine for tilapia that is indicated to reduce mortality and disease development due to Streptococcus caused by Streptococcus agalactiae biotype 2.
AQUAVAC® Strep Sa provides specific protection against S. agalactiae serotype lb infections in tilapia. In a large-scale field trial in an environment challenged by S. agalactiae serotype Ib, tilapia vaccinated with AQUAVAC® Strep Sa saw a significant improvement in mortality, increased biomass of 15.6 percent, and feed conversion efficiency was improved by 10 percent when compared with unvaccinated control fish.
Causative agent: Streptococcus agalactiae serotype lb
Indications: AQUAVAC® Strep Sa is for the active immunization of tilapia to reduce mortality and disease due to Streptococcosis caused by Streptococcus agalactiae.
Administration/Dosage: Prior to vaccination, food should be withheld for at least one day, tools should be sterile, and fish should be under anesthesia. Stress should be avoided before and after the vaccination. Shake the vaccine before administering 0.05 ml into the intra-peritoneal cavity, halfway between the base and the tip of the pelvic fins. Ensure the needle penetrates through the muscle wall and ideally deposits the vaccine into the visceral fatty area.
With AQUAVAC® Strep Sa, the duration of immunity against S. agalactiae serotype Ib infections has been demonstrated to last at least 30 weeks after vaccination. This means that greater numbers of healthier fish can be produced and sold, boosting productivity and maximizing returns.
To download this factsheet you must be logged in to Aquavac. Login now
Download the AQUAVAC® technical bulletin for more information on performance and quality of AQUAVAC® Strep Sa. This 8 page issue includes valuable material on laboratory trials conducted and the immediate results of this reliable vaccine.